Drug device combination lock-down!

1nhaler is proud to confirm the drug device combination design freeze of the 1nhaler clinical proof of concept product.

Design lockdown of both the device and the formulation ensures the company is on track to progress to GMP manufacture this summer. 1nhaler appointed Upperton Pharma Solutions as our CDMO partner earlier this year.

The latest data shows comparability to the gold standard DPI reference product.

This is a critical milestone in the development of our launch product, 1nhaler Salbutamol. It is testament to the skills and commitment of the 1nhaler research and development team led by Helen Muirhead and the ongoing support of Inhalytic Limited.